For adult patients with moderately to severely active UC or CD when other therapies have not worked well enough or cannot be tolerated.
Discover the latest Entyvio data and peer perspectives shared at these annual scientific congresses.
December 14-16, 2023 | Lake Buena Vista, FL
Advances in Inflammatory Bowel Diseases (AIBD)
You are about to leave this website.
By clicking "Continue," you will leave this site and enter TakedaMedConnect.com. The information contained on Takeda MedConnect is intended for U.S. healthcare professionals only in response to a specific request for medical information.
You are about to leave this website and enter a website operated by an independent third party.
The links to third-party websites contained on this website are provided solely for your convenience. Takeda does not control the content contained on any third-party website linked from this website. Your activities at those websites will be governed by the policies and practices of those third parties.
Please select "Continue" if you wish to be taken to this third-party website.